Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

Sunnybrook Health Sciences Centre

15 clinical trials · 15 recruiting · OTHER

Sunnybrook Health Sciences Centre has 15 clinical trials registered on ClinicalTrials.gov, with 15 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Sunnybrook Health Sciences Centre\'s Trial Portfolio

Sunnybrook Health Sciences Centre is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

15 of Sunnybrook Health Sciences Centre's 15 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Sunnybrook Health Sciences Centre's research footprint spans Breast Cancer (1 trials), radiation-dermatitis (1), and oligoprogressive (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Sunnybrook Health Sciences Centre's portfolio at 33% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Sunnybrook Health Sciences Centre

RECRUITINGPhase 3NCT06915857

Topical Betamethasone Versus Moisturizer in Preventing Radiation Dermatitis in Large-Breasted Patients Treated in the...

Radiotherapy (RT) is common in the treatment of breast cancer, however, 95% of breast cancer patients are at risk of developing acute and chronic skin toxicities known as...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 2761 location
Breast CancerRadiation Dermatitis
RECRUITINGNCT04838899

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 301 location
OligoprogressiveCastration-Resistant Prostate Cancer
RECRUITINGNCT04053439

Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal'...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 1881 location
LymphomaChemotherapeutic Toxicity
RECRUITINGNCT07476781

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor,...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 601 location
Solid Tumor MalignanciesBrain MetastasasesLeptomeningeal Disease (LMD)
RECRUITINGNCT05023265

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 701 location
Renal Cell Carcinoma
RECRUITINGPhase 2NCT07279740

Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia

This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 121 location
Alzheimer s DiseaseAlzheimer Dementia (AD)Alzheimer Dementia+3
RECRUITINGPhase 1NCT07193953

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 61 location
Amyotrophic Lateral SclerosisALS
RECRUITINGNCT05845541

Meditation and Biofeedback to Improve Anxiety, Depression and Quality of Life in Inpatients After Stroke

The goal of this clinical trial is to investigate the impact of a technology-based meditation program in the inpatient stroke population. It will explore how this approach can...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 601 location
Stroke
RECRUITINGPhase 1NCT06818864

DBS for Cognitive Deficits After Traumatic Brain Injury

Patients with memory and cognitive deficits following TBI that do not respond to conventional treatments experience a decrease in quality of life. Despite advances in...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 101 location
TBI Traumatic Brain Injury
RECRUITINGPhase 1NCT06705296

Deep Brain Stimulation for Refractory PTSD

Treatment refractory PTSD is a chronic and debilitating psychiatric disorder associated with high morbidity. Despite advances in neuroimaging, genetics, pharmacology and...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 201 location
PTSD
RECRUITINGPhase 1NCT02648009

Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection

The prevalence of congestive heart failure (CHF) in Canada is high, representing one of the health care system's most expensive diagnoses. Despite major advances in medicine, the...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 1122 locations
HypertensionHypertrophy
RECRUITINGNCT06309862

Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy

Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis and cardiomyopathy....

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 151 location
Cardio-OncologyCardiomyopathy Due to Drug
RECRUITINGPhase 3NCT03559114

PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 110012 locations
Traumatic Brain Injury
RECRUITINGNCT07108257

Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Depression

The goal of this clinical trial is to evaluate the safety and initial effectiveness of MR-guided focused ultrasound (MRgFUS) bilateral capsulotomy in patients with...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 101 location
Treatment-Resistant DepressionBipolar Depression
RECRUITINGPhase 4NCT07245732

Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to...

Sponsor: Sunnybrook Health Sciences CentreEnrolling: 2205 locations
Rheumatoid Arthritis (RA)

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Sunnybrook Health Sciences Centre have on ClinicalTrials.gov?

Sunnybrook Health Sciences Centre has 15 clinical trials registered on the federal ClinicalTrials.gov registry, of which 15 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Sunnybrook Health Sciences Centre study?

Sunnybrook Health Sciences Centre's registered trials cover 20 conditions on ClinicalTrials.gov, led by Breast Cancer (1 trial), radiation-dermatitis (1 trial), oligoprogressive (1 trial), Castration-resistant Prostate Cancer (1 trial), Lymphoma (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Sunnybrook Health Sciences Centre clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 15 trials tracked for Sunnybrook Health Sciences Centre.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.